
MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma
Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis. For a decade, sorafenib, a multi-kinase inhibitor, was the only approved systemic therapy for HCC. However, its response rate in advanced HCC is only about 2%. The last few years have seen rapid approval of additional systemic therapies for HCC, including immunotherapy strategies. Immune checkpoint inhibitor nivolumab has a promising reported response